CTLA4 and melanoma: This study assesses trends in incidence of neurologic irAEs in melanoma patients undergoing PD-1 inhibitor monotherapy compared to those receiving both anti-PD-1 and anti-CTLA-4 immunotherapies over time, unveiling insight into the relative risks associated with these treatment regimens.